Aktualności

O Instytucie

Misja i Władze

HR Excellence

Historia

Dla mediów

Studia doktoranckie

Stopnie naukowe

Działalność naukowa

Oferta Instytutu

MCB

Wydawnictwa

Centrum Konferencyjne

Biblioteka

Użyteczne linki

Pracownicy

Galeria

Kontakt

Pomoc

Aktualności
  • Main-Slider-PL-01
  • Main-Slider-PL-18
  • Main-Slider-PL-09
  • Main-Slider-PL-04
  • Main-Slider-PL-10
  • Main-Slider-PL-03
  • Main-Slider-PL-12
  • Main-Slider-PL-06
  • Main-Slider-PL-16
  • Main-Slider-PL-20
  • Main-Slider-PL-08
  • Main-Slider-PL-15
  • Main-Slider-PL-14
  • Main-Slider-PL-05
  • Main-Slider-PL-07
  • Main-Slider-PL-02
  • Main-Slider-PL-19
  • Main-Slider-PL-13
home 001 24px kontakt 001 24px  mail 004 24px bip text   

Serdecznie zapraszamy na seminarium Zakładu IV

Jakob N Kather, MD/MSc, z German Cancer Research Center, Heidelberg, Germany and RWTH University Hospital, Aachen, Germany
wygłosi wykład pt. : „Cancer immunotherapy: What is it about and how can we model it?”

Seminarium odbędzie się w dniu 22 października o godz. 13:00 w Sali S90

Zapraszamy

Cancer immunotherapy: What is it about and how can we model it?

Streszczenie: In the last few years, immunotherapy has revolutionized the treatment of cancer and has been rewarded with the 2018 Nobel prize in Medicine. For several cancer types, immunotherapy drugs can turn the body's immune system against malignant tumor cells, leading to longer survival or even cure of patients.
Immunotherapy acts on the interface of the immune system and cancer cells. Together, these cells form a complex ecosystem that is governed by nonlinear interactions. Understanding this system is important to understand and improve immunotherapy.
We are using mathematical and computational modeling based on biological and clinical data to understand this system. In particular, we employ agent-based models and ordinary differential equations as two complementary ways of understanding cancer-immune interactions. We show that these methods can achieve three goals: First, to understand how immunotherapy works and which factors limit its effects. Second, to predict which patient will benefit from immunotherapy. Third, to improve immunotherapy strategies and to find optimal drug combinations for a given patients.
Interdisciplinarity is key for these types of models and this talk will engage life scientists, physical scientists, mathematicians and other scientists alike.

MENU

POWER Och!DOK

HR Excellence

Nagrody naukowe


Instytut Biocybernetyki i Inżynierii Biomedycznej im. Macieja Nałęcza PAN, ul. Ks. Trojdena 4, 02-109 Warszawa
E-mail:Ten adres pocztowy jest chroniony przed spamowaniem. Aby go zobaczyć, konieczne jest włączenie w przeglądarce obsługi JavaScript.; Telefon: (+48) 22 592 59 00; Fax: (+48) 22 659 70 30
Copyright(c) 2016 IBIB PAN
Wszelkie prawa zastrzeżone

-->